Sign in

    Adam Walsh

    Managing Director and Senior Analyst at Stifel, Nicolaus & Company, Inc.

    Adam Walsh, M.D., is a Managing Director and Senior Analyst at Stifel, Nicolaus & Company, specializing in healthcare equity research with a primary focus on biotechnology and related sectors. He covers 23 healthcare companies and has established a performance track record marked by a 45.10% success rate and 3.58-star analyst rating on TipRanks. Walsh joined Stifel in October 2015, based in the Boston office, after previous roles in the healthcare investment field; he holds FINRA registration and maintains relevant securities licenses. His professional credentials, combined with his clinical background as an M.D., have positioned him among the respected analysts in biotech equity research.

    Adam Walsh's questions to Protagonist Therapeutics (PTGX) leadership

    Adam Walsh's questions to Protagonist Therapeutics (PTGX) leadership • Q4 2019

    Question

    Adam Walsh from Stifel, Nicolaus & Company, Inc. asked about the specific clinical thresholds for announcing PTG-300 data, whether a twice-weekly dosing regimen is being considered for indications other than beta-thalassemia, and for comments on competition from Morphic's oral alpha-4-beta-7 integrin competitor.

    Answer

    CFO Donald Kalkofen and President and CEO Dinesh Patel explained that the threshold for announcing PTG-300 data is reaching a point of certainty that warrants moving into a registration program, with the primary goal of selecting the first pivotal indication in 2020. Regarding dosing, they noted the study design allows for flexibility, but the goal is always the lowest, least frequent dose possible. Mr. Patel acknowledged awareness of competitors like Morphic but declined to comment on their programs.

    Ask Fintool Equity Research AI